GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 73.21B |
| Revenue (ttm) | 32.17B |
| Net Income (ttm) | 5.49B |
| Shares Out | 4.01B |
| EPS (ttm) | 1.33 |
| PE Ratio | 13.73 |
| Forward PE | 10.18 |
| Dividend | 0.61 (3.34%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 742,621 |
| Average Volume | 7,082,934 |
| Open | 1,828.00 |
| Previous Close | 1,824.50 |
| Day's Range | 1,823.50 - 1,849.00 |
| 52-Week Range | 1,242.50 - 1,853.50 |
| Beta | 0.25 |
| RSI | 56.83 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
GSK (GSK) Among Drugmakers Planning January Price Hikes for Medications
GSK (GSK) Among Drugmakers Planning January Price Hikes for Medications
Pfizer and GSK Lead 2026 U.S. Drug Price Hikes
Pfizer and GSK Lead 2026 U.S. Drug Price Hikes
Pfizer (PFE) and GSK (GSK) Plan Significant Drug Price Increases
Pfizer (PFE) and GSK (GSK) Plan Significant Drug Price Increases
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial
On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of o...
GSK To Lower Drug Prices
(RTTNews) - GSK plc (GSK, GSK.L) has entered into an agreement with the U.S. Administration to lower the cost of prescription medicines for American patients, including GSK's respiratory portfolio. GS...
Samsung Biologics acquires Human Genome Sciences from GSK
Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln
(RTTNews) - Samsung Biologics (207940.KS) announced that its wholly owned U.S. subsidiary, Samsung Biologics America, will acquire 100% of Human Genome Sciences from GSK (GSK, GSK.L) for US$280 millio...
Samsung Biologics to Acquire Human Genome Sciences from GSK
Samsung Biologics to Acquire Human Genome Sciences from GSK
Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln
South Korea's Samsung Biologics said on Monday its U.S. unit is buying a U.S. drug production facility from GSK for $280 million.
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 li...
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
GSK Reduces Medicine Costs in New U.S. Agreement
GSK Reduces Medicine Costs in New U.S. Agreement
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 Therapeutics Corporation (NASDAQ: CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE: GSK). The collaboration aims to identify and dev...
GSK (GSK) Resubmits New Drug Application for Antibiotic
GSK (GSK) Resubmits New Drug Application for Antibiotic
GSK: 2026 Looks Good
A Look Into GSK Inc's Price Over Earnings
In the current market session, GSK Inc. (NYSE: GSK) stock price is at $48.55, after a 0.33% decrease. However, over the past month, the company's stock spiked by 5.29% , and in the past year, by 44.4...
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...
CAMP4 Therapeutics Teams With GSK On ASO Drug Candidates
(RTTNews) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide (ASO) dru...
GSK Gains Approval for New Asthma Treatment, Boosting Stock
GSK Gains Approval for New Asthma Treatment, Boosting Stock